News >

Understanding the Implications of Mutational Status in Intrahepatic Cholangiocarcinoma

Angelica Welch
Published: Tuesday, Jan 09, 2018

Jesper B. Andersen, MSc, PhD
Jesper B. Andersen, MSc, PhD
There continues to be a dramatic increase in both incidence and mortality rate of cholangiocarcinoma worldwide, according to Jesper B. Andersen, MSc, PhD.

, Andersen, who is an associate professor and leader of the Andersen Group at Biotech Research and Innovation Centre, Department of Health and Medical Sciences at the University of Copenhagen, discussed the findings of this study and the implications it could have on the future treatment of patients with cholangiocarcinoma.

OncLive: Can you please provide an overview of this study?

Andersen: The study is focused on tumors that arise in the bile duct epithelium within the liver, meaning they are anatomically classified as intrahepatic cholangiocarcinomas. That was a deliberate strict inclusion of patients into this study to introduce minimal genomic heterogeneity, because cholangiocarcinoma is a tumor type that exists both in the liver and right outside the liver (extrahepatic). We used a total cohort size of 496 intrahepatic tumors, and analyzed these by whole-exome sequencing, targeted-exome sequencing, transcriptomics, structural variances, and DNA methylation.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x